[{"id":"f40873ca-e3ed-4dcf-90c0-5527c131aaed","acronym":"","url":"https://clinicaltrials.gov/study/NCT05891171","created_at":"2023-06-06T14:07:07.271Z","updated_at":"2024-07-02T16:35:01.204Z","phase":"Phase 1","brief_title":"Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers","source_id_and_acronym":"NCT05891171","lead_sponsor":"Arcus Biosciences, Inc.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • 5-fluorouracil • pemetrexed • oxaliplatin • Yutuo (zimberelimab) • leucovorin calcium • AB598"],"overall_status":"Recruiting","enrollment":" Enrollment 81","initiation":"Initiation: 10/13/2023","start_date":" 10/13/2023","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2024-05-24"}]